

ABOUT  
**SMA**  
SPINAL MUSCULAR ATROPHY



**Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that affects the part of the nervous system that controls voluntary muscle movement.** It is caused by a mutation of the survival motor neuron 1 (SMN1). In a healthy person, this gene produces a protein that is essential to the function of the nerves that control muscles. Without it, those nerve cells cannot function properly and eventually die, leading to debilitating muscle function and often fatal muscle weakness.

There are four primary types of SMA based on age of onset and the manifestation of the disease:<sup>1,2</sup>

- **Type I**, also known as Werdnig-Hoffmann disease, is the most common and most severe form of SMA, and the leading genetic cause of death for infants.
- **Type II** is diagnosed in children between the ages of 6 months and 2 years. The symptoms are less severe than Type I but become more noticeable in older children.
- **Type III**, also known as Kugelberg-Welander disease or juvenile SMA, is the mildest form of childhood SMA and typically does not shorten life expectancy.
- **Type IV** is very rare, usually appearing after age 35 with mild to moderate symptoms.

**PREVALENCE OF SMA**

SMA affects between 10,000 and 25,000 adults and children in the U.S. and accounts for 1 in 6,000 to 1 in 10,000 live births per year. Around eighty percent of the prevalent population is Type I or Type II. SMA can affect any race or gender.<sup>1,3</sup>

**SYMPTOMS AND PROGNOSIS OF SMA**

Symptoms and life expectancy vary from mild to severe, depending on the type of SMA. The most severe symptom of SMA is the weakening of the muscles necessary for breathing. In general, patients with SMA experience deterioration in their condition over time, but the prognosis varies depending on the type of SMA and the degree of respiratory impairment.<sup>3</sup>

**DIAGNOSING SMA**

Children with SMA generally appear normal at birth, but symptoms can develop in the first few months of life. For 95% of SMA Types I, II and III, a diagnosis of SMA can be confirmed by a blood test designed to identify genetic defects in the SMN1 gene.<sup>4</sup> In rare cases, doctors may order a muscle biopsy or tests to measure nerve conduction velocity and electrical activity in muscle.

**TREATING SMA**

Currently there is one FDA-approved treatment for SMA, Spinraza, an antisense oligonucleotide that targets SMN2, often referred to as the SMA "backup gene," causing it to make more complete SMN protein. In addition, treatment consists of managing symptoms and preventing complications, which may include physical therapy, muscle relaxants, heat application to relieve muscle pain and assistive devices such as supports, braces, orthotics or wheelchairs. Some individuals require additional therapy for speech, chewing and swallowing, and may require a feeding tube or assisted ventilation. Proper nutrition is also essential to maintaining weight and strength.<sup>4</sup>

SMA TYPE	SEVERITY	PERCENT OF PREVALENT POPULATION	AGE OF ONSET	SYMPTOMS	HIGHEST FUNCTION	LIFE EXPECTANCY
Type I (Infantile)	Severe	~10%	0-6 months	Very weak; difficulty breathing, sucking and swallowing	Unable to sit	<2 years
Type II (Intermediate)	Intermediate	~34%	6-18 months	Respiratory complications are common	Sits but unable to stand or walk independently	>2 years
Type III (Juvenile)	Mild	~45%	>18 months	Stands and walks	Can stand and walk, but with mobility issues later in life	Near normal
Type IV (Adult)	Mildest	~11%	Adult onset	Mild motor impairment	Able to walk, with gradual weakness and mobility issues later in life	Normal

### ABOUT CK-2127107

In collaboration with Astellas, Cytokinetics is developing CK-2127107 (CK-107), a next-generation fast skeletal troponin activator (FSTA) as a potential treatment for people living with SMA, COPD and certain other debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness and/or muscle fatigue. CK-107 is an investigational drug candidate intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which may improve muscle function and

physical performance in people with SMA.

CK-107 has been the subject of five Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics. It is currently the subject of two Phase 2 clinical trials, one assessing its effect on multiple measures of muscle function in patients with Type II, Type III, or Type IV SMA, and one evaluating its effect on physical function and exercise tolerance in patients with COPD.



**Cytokinetics, Inc.**  
 280 East Grand Avenue  
 South San Francisco, CA 94080  
 650 624 3000  
 cytokinetics.com

### References

1. SMA Foundation. SMA Overview. Available at: <http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf>. Accessed March 5, 2016.
2. CureSMA. Types of SMA. Available at: <http://www.curesma.org/sma/about-sma/types-of-sma/>. Accessed March 5, 2016.
3. D'Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. Spinal muscular atrophy. *Orphanet journal of rare diseases*. 2011; 6(1), 1-10.
4. NIH. Spinal Muscular Atrophy Fact Sheet, 2015. Available at: [http://www.ninds.nih.gov/disorders/sma/detail\\_sma.htm](http://www.ninds.nih.gov/disorders/sma/detail_sma.htm). Accessed March 5, 2016.

### Forward Looking Statements

This fact sheet contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities, including the conduct, design, enrollment and progress of the Phase 2 clinical trial of CK-2127107 in patients with SMA and the Phase 2 clinical trial of CK-2127107 in patients with COPD; the significance and utility of preclinical study and clinical trial results; and the properties and potential efficacy and safety profile of CK-2127107 and Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Astellas' decisions with respect to the design, initiation, conduct, timing and continuation of development activities for CK-107; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.